Breaking News | Real-time commentary on the market, with links to key sources.

Thursday, August 28 2008
  • 12:38 PM Amgen (AMGN) will no longer offer rebates on its anemia drug Aranesp, after critics argued that the rebates contributed to overprescription. Amgen said it will instead offer bigger discounts at the time of purchase.